GBMA chair Professor Jane Halton AO PSM said economic modelling shows that each biosimilar molecule listed on the PBS could return up to $100 million to the health budget.
GBMA says Australia can benefit from a biosimilar medicines funding windfall
November 20, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The effort to change an institution from within, works best when exit is possible
October 15, 2026 - - Latest News -
The medicines gap costing Australian children time they can't get back
October 15, 2026 - - Latest News -
Brain cancer advocates return to Canberra 'to keep that ambition alive'
October 15, 2026 - - Latest News -
Priceline Pharmacy puts its name on the Diamonds as netball rides record growth
October 14, 2026 - - Latest News -
Until the law changes what the committee is instructed to weigh, these processes will deliver nothing
October 14, 2026 - - Latest News -
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
October 14, 2026 - - Latest News -
Peter Mac taps Sydney manufacturer to test its solid tumour CAR T therapy
October 14, 2026 - - Latest News
